Skip to main content

Table 6 Descriptive statistics of secondary outcome measured at baseline, 3 month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups

From: Is tailored treatment superior to non-tailored treatment for pain and disability in women with non-specific neck pain? A randomized controlled trial

Secondary Outcomes TT NTT TAU TT vs NTT TT vs TAU NTT vs TAU
Estimated mean (SD) Estimated mean (SD) Estimated mean (SD) Effectsb (95 % CI) Effectsb (95 % CI) Effectsc (95 % CI)
ProFitMap intensity
 Baseline 71.64 (11.38) 71.55 (11.38) 70 (11.38)    
 3 month 79.61 (11.02) 80.84 (11.16) 72.07 (11.07) −1.31
(-3 to 5.62)
5.9
(1.51 to 10.29)**
7.21
(2.88 to 11.54)**
 9 month 78.48 (11.07) 81.49 (11.16) 75.91 (11.24) −3.09
(-1.22 to 7.40)
0.92
(-3.49 to 5.33)
4.01
(-0.32 to 8.34)
 15 month 78.5 (11.02) 82.1 (11.22) 76.98 (11.18) −3.67
(-0.64 to 7.98)
−0.13
(-4.48 to 4.22)
3.54
(-0.79 to 7.87)
ProFitMap frequency
 Baseline 66.02 (14.67) 67.74 (14.67) 64.08 (14.67)    
 3 month 78.19 (14.05) 78.69 (14.22) 67.28 (14.16) 1.22
(-3.91 to 6.35)
8.97
(3.74 to 14.2)***
7.73
(2.56 to 12.9)**
 9 month 75.74 (14.05) 76.09 (14.28) 71.44 (14.25) 1.38
(-3.75 to 6.51)
2.36
(-2.85 to 7.57)
0.98
(-4.19 to 6.15)
 15 month 75.76 (14.05) 78.73 (14.34) 72.88 (14.25) −1.24
(-6.41 to 3.9 )
0.95
(-4.26 to 3.61)
2.19
(-2.98 to 7.36)
PGICS
 3 month 2.20 (1.1) 2.19 (1.14) 3.64 (1.1) 0.01
(-0.52 to 0.54)
1.44
(0.9 to 1.98)***
1.45
(0.93 to 1.97)***
 9 month 2.5 (1.16) 2.53 (1.14) 3.13 (1.18) 0.04
(-0.49 to 0.57)
0.8
(0.31 to 1.29)**
0.85
(0.38 to 1.32)***
 15 month 2.49 (1.16) 2.47 (1.14) 3.18 (1.18) −0.005
(-0.48 to 0.46)
0.75
(0.28 to 1.22)**
0.75
(0.28 to 1.22)**
PPT right
 Baseline 223.4 (102.7) 209.8 (102.8) 209.2 (102.8)    
 3 month 251.6 (99.5) 237 (100.4) 203.3 (100.2) 1.03
(-38.4 to 40.4)
34.1
(-6.1 to 74.3)
33.06
(-6.6 to 72.8)
 9 month 251.5 (100.1) 263 (100.5) 228.4 (102.3) −25.10
(-65.7 to 14.5)
8.92
(-31.4 to 49.3)
34.03
(-5.7 to 73.7)
PPT left
 Baseline 218.1 (95.8) 204.9 (95.8) 212.3 (95.8)    
 3 month 247.6 (93.3) 223.4 (94.1) 197.3 (94.2) 11.01
(-28.8 to 50.9)
44.49
(3.7 to 85.2)*
33.47
(-6.6 to 73.6)
 9 month 244.8 (94.1) 243.7 (93.5) 224.6 (95.6) −11.99
(-52.1 to 28.1)
14.46
(-26.3 to 55.2)
26.45
(-13.65 to 66.6)
Work Quantity
 Baselined 8.51 (1.58) 8.79 (1.58) 7.95 (1.51)    
 3 month 9.23 (1.63) 9.15 (1.56) 8.91 (1.51) 0.36
(-0.46 to 1.18)
−0.25
(-1.07 to 0.57)
−0.61
(-1.47 to 0.19)
 9 month 9.58 (1.63) 9.24 (1.56) 8.94 (1.53) 0.62
(-0.2 to 1.44)
0.07
(-0.75 to 0.89)
−0.55
(-1.16 to 0.25)
 15 month 9.75 (1.63) 9.09 (1.56) 9.5 (1.53) 0.94
(0.12 to 1.76)*
−0.32
(-1.14 to 0.5)
−1.26
(-2.06 to -0.46)**
Work Quality
 Baselinee 7.43 (1.83) 8.32 (1.89) 7.53 (1.86)    
 3 month 8.77 (1.86) 9.06 (1.8) 8.58 (1.74) 0.61
(-0.31 to 1.53)
0.28
(-0.64 to 1.2)
−0.32
(-1.22 to 0.58)
 9 month 9.18 (1.86) 9.0 (1.8) 8.52 (1.77) 1.08
(0.16 to 2)*
0.76
(-0.16 to 1.68)
−0.32
(-1.22 to 0.58)
 15 month 9.36 (1.86) 9.09 (1.8) 9.11 (1.77) 1.17
(0.25 to 2.09)*
0.34
(-0.58 to 1.26)
−0.82
(-1.72 to 0.08)
  1. TT tailored treatment group, NTT non-tailored treatment group, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval; PGICS patient global impression of change scale, PPT pressure pain threshold; b Positive values of effects favor the tailored treatment group; c Positive values of effects favor the non-tailored treatment group; d TAU, significant lower (p < 0,05) than NT; e TT, significant lower (p < 0,05) than NTT; * comparison is significant at the 0,05 level, ** comparison is significant at the 0,01 level, *** comparison is significant at the 0,001 level